Business
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results
LOS ANGELES, April 23, 2026--Puma Biotechnology will host a conference call on May 7 at 1:30 p.m. PT, following release of its first quarter 2026 financial results.
About this update from Puma Biotechnology Inc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2400,"height":800,"url":"https://media.zenfs.com/en/business-wire.com/83ccd5256b5a35e3faec02cd09435e9a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dxP56MsDv_zGCd2n16qa6g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyMA--/https://media.zenfs.com/en/business-wire.com/83ccd5256b5a35e3faec02cd09435e9a","width":960,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Oxq4QpzlNsdmXvEwXw92yw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MDA-/https://media.zenfs.com/en/business-wire.com/83ccd5256b5a35e3faec02cd09435e9a","width":1200,"height":400}},"lazy":false},{"type":"text","content":"LOS ANGELES, April 23, 2026--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, May 7, 2026, following the release of its first quarter 2026 financial results.","length":265,"tagName":"p"},{"type":"text","content":"The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available approximately one hour after completion of the call and will be archived on Puma’s website for 90 days.","length":564,"tagName":"p"},{"type":"text","content":"About Puma Biotechnology","length":24,"tagName":"p"},{"type":"text","content":"Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA ...